Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.45 |
| ▸ | ALPL | P05186 | 2/20 | 0.44 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | PRF1 | P14222 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716553 | 0.94 | LMNA (0.53) | LMNAL3MBTL1MAPK10PFKFB3MAPT | |
| SCHEMBL6724669 | 0.92 | PFKFB3 (0.53) | LMNAMAPK10PFKFB3MAPTTP53 | |
| SCHEMBL6718368 | 0.88 | LMNA (0.51) | LMNAL3MBTL1MAPK10PFKFB3MAPT | |
| SCHEMBL7210302 | 0.88 | LMNA (0.48) | LMNAL3MBTL1MAPK10PFKFB3MAPT | |
| SCHEMBL7210296 | 0.87 | PFKFB3 (0.56) | LMNAMAPK10PFKFB3MAPTTP53 | |
| SCHEMBL6720387 | 0.86 | PFKFB3 (0.52) | LMNAMAPK10PFKFB3MAPTTP53 | |
| SCHEMBL6779986 | 0.85 | CYP19A1 (0.43) | LMNAMAPK10MAPTTP53MAPK9 | |
| SCHEMBL6720455 | 0.84 | MAPK10 (0.46) | LMNAL3MBTL1MAPK10PFKFB3MAPT | |
| SCHEMBL6724930 | 0.83 | GSPT1 (0.45) | MAPK10TP53MAPK9MAPK14ITGA1 | |
| SCHEMBL6718416 | 0.82 | TRIM24 (0.45) | LMNAL3MBTL1MAPK10PFKFB3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818651-B2 | ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | US | disclosed |
| EP-1337515-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002040450-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | PDE7B, PDE3B, PDE3A | LMNA 1790/4885L3MBTL1 4650/4885MAPK10 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.